Список проголосовавших за комментарий "Victor Nelin, вы сами читаете ссылки, которые кидаете?<br/> According to IBD, the CANSLIM strategy does still work, claiming a 20.7% average annual return. IBD provides no audited evidence to back up this assertion. The CANGX and Innovator IDB 50 ETF based on CANSLIM have underperformed the market. The academic research “OPBM II” is outdated and no longer valid.<br/> <br/> "